• Voyager Therapeutics, Inc. reported fourth-quarter 2025 results showing a net loss of US$27.43 million versus US$34.49 million a year earlier, while its full-year 2025 net loss widened to US$119.72 million from US$65.00 million.

• Although the quarterly loss per share from continuing operations narrowed to US$0.47 basic (US$0.46 diluted), the full-year loss per share increased to US$2.04 basic and diluted, underscoring the cost of advancing its neurology-focused pipeline.

• We’ll now examine how the narrower quarterly loss but larger full-year deficit may influence Voyager’s investment narrative and risk profile.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

Voyager Therapeutics Investment Narrative Recap

To own Voyager today, you need to believe that its neurology-focused gene therapy and tau programs will ultimately justify years of sizeable losses and partner dependence. The latest results, with a narrower Q4 2025 loss but a sharply higher full-year deficit of US$119.72 million, highlight an elevated cash burn. That increases near term execution and financing risk, even if the quarter itself does not appear to alter the timing of key clinical catalysts in a clear way.

In this context, the November 2025 collaboration with Transition Bio on ALS and FTD stands out. It ties directly into Voyager’s partnered-pipeline catalyst and its reliance on external funding, adding another potential source of future milestones alongside existing pharma relationships. Against a backdrop of widening annual losses, progress and durability in these partnerships may matter even more for how investors assess Voyager’s ability to sustain its R&D and reach value inflection points.

Yet beneath that promise, investors should also be aware of how Voyager’s dependence on milestone payments and a narrow tau focused pipeline could...

Read the full narrative on Voyager Therapeutics (it's free!)

Voyager Therapeutics’ narrative projects $92.0 million revenue and $13.0 million earnings by 2028. This requires 29.3% yearly revenue growth and a $120.9 million earnings increase from -$107.9 million today.

Uncover how Voyager Therapeutics' forecasts yield a $15.67 fair value , a 222% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenue could climb toward about US$138 million with positive earnings by 2028, which contrasts sharply with today’s deepening annual losses and highlights how views on the same tau focused pipeline and partnership milestones can differ widely, especially now that fresh numbers may prompt both bullish and cautious investors to rethink what comes next.